Overview

Physiologic Monitoring of Antidepressant Treatment Response

Status:
Completed
Trial end date:
2002-09-01
Target enrollment:
Participant gender:
Summary
Study Objectives: - to identify neurophysiologic effects of venlafaxine treatment in normal controls using quantitative EEG (QEEG) cordance - to examine the effects of venlafaxine on different rating scales measuring mood and anxiety (e.g., Ham-D, BDI, SCL-90, POMS-BI, Visual Analog Mood Scale, SSRS, SASS, Q-LES-Q and SF-36) as well as on measures of cognitive and psychosocial function (i.e., Stroop, PASAT, RAVLT, Trailmaking A and B, Digit-Symbol, Grooved Pegboard, Multidimensional Health Locus of Control, Temperament and Character Inventory, Interpersonal Support Evaluation List, Godin Leisure-Time Questionnaire, and Pittsburgh Sleep Quality Index) in normal control subjects, and the association of changes in cordance with changes in thinking and memory. - to identify physiologic effects of venlafaxine treatment in normal controls using heart rate and immune function measures
Phase:
Phase 4
Details
Lead Sponsor:
University of California, Los Angeles
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Antidepressive Agents
Venlafaxine Hydrochloride